Most Recent Stories
More News
Canopy Growth soars on reports the White House is considering reclassifying cannabis as a “Schedule III” drug. Here’s why CGC shares currently look attractive as a long-term holding.
Down almost 70% from all-time highs, Curaleaf stock offers significant upside potential given its widening free cash flow margins.
This news release constitutes a “designated news release” for the purposes of Canopy Growth’s prospectus supplement dated August 29, 2025 to its short form base shelf prospectus dated June 5, 2024...
New high-performance AIO vapes and infused pre-roll variety packs further Claybourne’s continued growth as one of the fastest-rising brands 1 in Canada’s adult-use market
Expanded formats strengthen Canopy Growth’s medical offering as patient demand rises
Canopy Growth’s latest results showcased stronger execution and renewed momentum across key markets. Is CGC stock finally turning the corner this November?
Canada adult-use revenue up 30% in Q2 FY2026 and 37% year-to-date, reflecting the benefits of our focused commercial strategy and more disciplined execution Canada medical...
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2026 ended September 30, 2025 before financial...
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, is pleased...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...